Ligand Pharmaceuticals (LGND) Short-term Investments (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Short-term Investments data on file, last reported at $664.3 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 312.85% year-over-year to $664.3 million; the trailing twelve-month figure through Mar 2026 stood at $664.3 million (up 312.85% YoY), and the FY2025 full-year result was $558.6 million, up 203.82% from the prior year.
• Short-term Investments grew to $664.3 million in Q1 2026, from $558.6 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $664.3 million in Q1 2026 to a low of $11.1 million in Q3 2024.
• A 5-year average of $228.3 million and a median of $177.4 million in 2025 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments sank 93.5% in 2024 and surged 4617.02% in 2025, its largest moves.
• Tracing LGND's Short-term Investments over 5 years: stood at $166.9 million in 2022, then declined by 11.69% to $147.4 million in 2023, then increased by 24.77% to $183.9 million in 2024, then soared by 203.82% to $558.6 million in 2025, then advanced by 18.93% to $664.3 million in 2026.
• Business Quant data shows LGND's Short-term Investments at $664.3 million in Q1 2026, $558.6 million in Q4 2025, and $525.1 million in Q3 2025.